SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending sharply lower after announcing that Marvell canceled all purchase orders inherited from its acquisition of Celestial AI due to an alleged breach of confidentiality. Investors and community members are expressing significant frustration over management's handling of the disclosure, leading to widespread speculation about the company's future contracts and immediate valuation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is seeing intense community speculation as investors anticipate a major short squeeze, driven by record high short interest and limited share availability. Enthusiastic supporters are highlighting the potential impact of Rumble's pending acquisition of Northern Data and strategic financial backing from Tether as catalysts that could fundamentally shift the stock's valuation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing significant market movement driven by speculative interest in its shift toward custom AI chip design and high-performance server CPUs. Community discussions are split between euphoria over its long-term potential as an AI infrastructure backbone and intense debate regarding its valuation, with many traders actively debating the merits of aggressive shorting versus holding for a potential parabolic breakout.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting intense investor interest as the company prepares for an oral presentation of its pancreatic cancer data at the upcoming Digestive Disease Week conference. The community is buzzing with anticipation over a strong pipeline of clinical catalysts, with many retail traders actively accumulating shares in expectation of a significant breakout.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense volatility and record-breaking volume as traders debate whether the semiconductor sector's prolonged winning streak represents an unsustainable AI bubble or a resilient super-cycle. Community sentiment remains deeply polarized between aggressive short-sellers betting on a mean reversion and bulls who argue that relentless momentum and capital rotation into chip-related infrastructure make shorting the sector a high-risk trade.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as retail and institutional investors capitalize on its pivot into high-margin custom AI silicon and optical connectivity, with community discourse centered on potential hyperscaler partnerships and structural demand for its networking infrastructure. Traders are closely monitoring the stock's parabolic ascent, fueled by reports of custom chip collaborations and significant options flow, as the community debates whether the momentum represents an infrastructure-led re-rating or a classic overextended squeeze.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Profusa Stock Tuesday?

Profusa ($PFSA) shares down 40% to $1.10. Company signs LOI for $30M acquisition to scale its diagnostics and monitoring business.read more...

Small Cap Stocks To Consider - April 6th

Inflection Point Acquisition, XIAO-I, Profusa, Direxion Daily MU Bull 2X Shares, Aehr Test Systems, SMX (Security Matters) Public, and Spring Valley Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of companies wit...

Top Manufacturing Stocks To Consider - April 6th

Taiwan Semiconductor Manufacturing, Profusa, and Applied Materials are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are shares of...

Medical Stocks To Watch Today - April 6th

Hologic, Soleno Therapeutics, Eli Lilly and Company, UnitedHealth Group, Profusa, Johnson & Johnson, and Amgen are the seven Medical stocks to watch today, according to MarketBeat's stock screener...

Billions in Play: The Hidden Land Grab Across AI, Biotech, and Precision Medicine

A fresh wave of dealmaking, platform expansion, and commercialization milestones is reshaping the narrative across emerging healthcare and AI-driven companies. $TGNT, $PFSA, $KBLB, $NBIX, $SLNO, $FCUV

<ul class="summary-bullets"><li>Profusa will gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools.</li><li>Profusa will pay BioInsights about $30 million in equity.</li><li>BioInsights will receive a 3% royalty on future net revenue.</li></ul>Shares of Profusa, Inc. (PFSA) surged 150% on Monday after the company announced plans to enter the molecular diagnostics space through a proposed acquisition of the PanOmics diagnostic platform from BioInsights.Under the agreement, Profusa would gain exclusive rights to the PanOmics platform and related expertise, including access to samples and tools, from BioInsights, for about $30 million. The consideration is payable in equity, the firm stated.BioInsights will receive a 3% royalty on future net revenue. The move is expected to add to Profusa’s real-time biochemistry monitoring technology.<h2 class="st-heading-2">Mayo Clinic Collaboration</h2>With access to clinical samples, a validation plan, and a partnership with the Mayo Clinic, the company believes it is well positioned to speed up development, increase clinical use, and create strong near-term growth.“The combination of the PanOmics platform and our collaboration with Mayo Clinic positions us to build a differentiated, scalable presence in precision diagnostics and surgical monitoring. The entry into pancreatic cancer is instrumental in our establishing a platform capable of supporting multiple indications and long-term growth,” said Ben Hwang, Profusa Chairman and CEO.&nbsp;<h2 class="st-heading-2">Potential For Recurring Revenue&nbsp;</h2>Combining the PanOmics platform with its biosensing technology could enable multi-indication diagnostics, real-time monitoring, and data-driven clinical tools, Profusa said. The company aims to expand into high-growth markets and build a scalable, recurring-revenue platform.&nbsp;It will also support its pancreatic cancer treatment efforts, using the Lumee oxygen system to improve monitoring during complex surgeries, a market with significant annual revenue potential.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/PFSA">PFSA</a> remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user expects the stock to be a multi-day runner following the news.<stembedurl>https://stocktwits.com/uppons/message/649485111</stembedurl>Another user expects the stock to rise to $1.94 due to strong volumes. It is currently at $1.85.<stembedurl>https://stocktwits.com/Twit_2_my_lou/message/649484322</stembedurl>Year-to-date, the stock has shed around 65%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PFSA Stock Surge 150% Today?

Profusa announced plans to acquire the PanOmics diagnostic platform from BioInsights.

Equity

Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transceiver order worth $71 million, bringing total orders from a major customer to $124 million. Other...

Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today

Profusa Stock Soars To 12 Cents On Debt Restructuring

Profusa stock soars after the company announced the restructuring of its debt and a reduction in potential shareholder dilution.read more...

Manufacturing Stocks To Add to Your Watchlist - December 30th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Profusa, FREYR Battery, Medline, and Phillips 66 are the seven Manufacturing stocks to watch today, according to...

Profusa, Inc. engages in the biofeedback for chronic disease management and healthy living services. The company is headquartered in Berkeley, CA.

PFSA
Profusa Inc.

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest PFSA News

PFSAProfusa Inc.